Key takeaways
ADHD affects a large number of children and adults in the United States, and the prevalence continues to increase.
Vyvanse and Ritalin are both stimulant medications for the treatment of ADHD and other conditions. Both are Schedule II controlled substances due to their potential for misuse.
Vyvanse and Ritalin have approved generic equivalents, which may provide more affordable treatment options.
Ritalin or Vyvanse may be more effective for some people or have different side effects. A healthcare professional can help guide treatment or switch medications if needed.
Attention-deficit hyperactivity disorder (ADHD) affects millions of children and adults in the U.S. It’s often managed with central nervous system (CNS) stimulant medications, like Vyvanse (lisdexamfetamine) and Ritalin (methylphenidate). These medications work differently, may have different costs and side effects, and may be more effective for certain individuals. Here’s a side-by-side comparison to help you better understand each option.
Main differences between Vyvanse vs. Ritalin | ||
---|---|---|
Vyvanse | Ritalin | |
Drug class | Central nervous system stimulant | Central nervous system stimulant |
Brand/generic status | Brand and generic available | Brand and generic available |
What is the generic name? | Lisdexamfetamine | Methylphenidate |
What form(s) does the drug come in? | Oral capsule and chewable tablet | Immediate-release oral tablet and long-acting oral capsule |
What is the standard dosage? | Adults and children: 30 to 70 mg daily | Adults: 10 to 60 mg daily
Children: Varies by age and weight |
How long is the typical treatment? | Long-term (months to years) | Long-term (months to years) |
Age group | 6+ | 6+ |
What are the main differences between Vyvanse and Ritalin?
Vyvanse is a central nervous system stimulant used in the treatment of ADHD and binge-eating disorder. The exact mechanism as to how Vyvanse treats these disorders is not known. Vyvanse is converted to its active metabolite, dextroamphetamine. Amphetamines stimulate the release of catecholamines, such as norepinephrine and dopamine, into the neuron synapse. These neurotransmitters play a critical role in mood and focus.
The U.S. Drug Enforcement Agency (DEA) deems Vyvanse a Schedule II drug, which means it has a high potential for abuse. Therefore, there may be restrictions and guidelines for obtaining Vyvanse, which differ by state. Vyvanse is an oral capsule available in 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. It is also available as a chewable tablet.
Ritalin is also a central nervous system stimulant used to treat ADHD and narcolepsy. Like Vyvanse, its exact mechanism is not fully understood. Rather than causing the release of catecholamines, it blocks the reuptake of those neurotransmitters in the neuron synapse. That leaves more available dopamine and norepinephrine, which affects mood and focus.
The DEA also classifies Ritalin as a Schedule II drug due to its abuse potential. It is available in immediate-release tablets in 5 mg, 10 mg, and 20 mg strengths. It is also available in a long-acting capsule formulation (Ritalin LA) in 10 mg, 20 mg, 30 mg, and 40 mg strengths.
Conditions treated by Vyvanse and Ritalin
Both Vyvanse and Ritalin are approved to treat ADHD in children, adolescents, and adults. Vyvanse is also approved to treat binge-eating disorder, while Ritalin is used to manage narcolepsy. Some healthcare providers may prescribe these medications off-label for other conditions like severe fatigue or depression.
Is Vyvanse or Ritalin more effective?
A 2017 review found that Vyvanse showed greater improvement in ADHD symptoms in children but was more likely than Ritalin to be stopped because of side effects. A 2020 review of ADHD treatment trials in adults did not show a significant difference between medications in symptom improvement or side effects. Effectiveness and side effects often vary by person. What works best for you depends on your medical history, how your body responds to treatment and potential interactions with other medications. Your healthcare provider will work with you to find the safest and most effective treatment.
Coverage and cost comparison of Vyvanse vs. Ritalin
Vyvanse is a prescription medication typically covered by commercial insurance. Some Medicare plans may cover Vyvanse but require prior authorization or have a higher copay. The out-of-pocket price for 30 capsules of brand-name Vyvanse 30 mg can be $570. A coupon from SingleCare can bring the price of generic Vyvanse 30 mg to $75 at select pharmacies.
Ritalin is also a prescription medication typically covered by commercial insurance. Coverage by Medicare plans may vary or require special exceptions. Ritalin typically retails for around $140 per 60 20 mg tablets, but with a coupon from SingleCare, a one-month supply of generic Ritalin may cost as little as $23.
Ritalin LA, approved for children ages 6-12, typically costs $455 for 30 of the 20 mg extended-release capsules. However, with a SingleCare coupon, that cost may be lowered to $57 for a one-month supply of generic Ritalin LA capsules.
Vyvanse | Ritalin | |
Typically covered by insurance? | Yes | Yes |
Typically covered by Medicare? | Possibly with prior authorization | Possibly with prior authorization |
Standard dosage | 30 to 70 mg daily | 10 – 60 mg divide twice daily, or
20 – 40 mg LA once daily |
Typical Medicare copay | Variable | Variable |
SingleCare cost | $75-124 | $16-26
$57 (LA capsules) |
Common side effects of Vyvanse and Ritalin
Since they’re both CNS stimulants, Vyvanse and Ritalin share many side effects. These medications should be taken in the morning to avoid disrupting sleep.
Common side effects of Vyvanse and Ritalin may include:
- Insomnia
- Decreased appetite
- Weight decrease
- Abdominal pain, nausea, and vomiting
- Irritability and mood changes
- Dry mouth
- Dizziness
This is not a complete list of side effects. Side effects vary by person and age and should be discussed with a healthcare provider.
Drug interactions of Vyvanse and Ritalin
Vyvanse and Ritalin should never be taken with monoamine oxidase inhibitors (MAOIs) due to the risk of a hypertensive crisis. Both can also interact with other classes of medications, including:
Drug | Drug Class | Interaction Effect |
Selegiline
Isocarboxazid Phenelzine Linezolid |
Monoamine oxidase inhibitors (MAOIs) | Dangerously high blood pressure |
Fluoxetine
Paroxetine Sertraline Citalopram Escitalopram |
Selective serotonin reuptake inhibitors (SSRIs) | Serotonin syndrome |
Venlafaxine
Duloxetine Desvenlafaxine |
Selective norepinephrine reuptake inhibitors (SNRIs) | Serotonin syndrome, high blood pressure |
Sumatriptan
Rizatriptan Eletriptan Zolmitriptan Naratriptan Frovatriptan |
5HT3 Antagonists (Triptans) | Serotonin syndrome, high blood pressure |
Desipramine
Protriptyline Amitriptyline Nortriptyline |
Tricyclic antidepressants | Serotonin syndrome, high blood pressure, dangerous heart rhythms |
Lisinopril
Ramipril Benazepril Enalapril Quinapril Fosinopril |
Angiotensin-converting enzyme (ACE) inhibitors | High blood pressure |
Losartan
Irbesartan Valsartan Olmesartan |
Angiotensin receptor blockers (ARBs) | High blood pressure |
Carvedilol
Metoprolol Atenolol Nebivolol |
Beta blocker | High blood pressure |
Other interactions are possible, including with some herbal supplements such as St. John’s wort. Tell your healthcare provider about all prescription and over-the-counter medications you take, as well as vitamins, herbal treatments, and supplements.
Warnings of Vyvanse and Ritalin
Both drugs have a high potential for abuse and are classified as Schedule II controlled substances. They can increase the risk of heart problems, especially in people with preexisting conditions. They may also worsen psychiatric symptoms or cause new ones. Always follow your provider’s instructions closely and report any new, unusual, or worsening symptoms.
Switching medications
If one form of ADHD treatment isn’t working as well as needed, or if you’re experiencing too many side effects, you and your healthcare provider may consider switching medications. There are a few important aspects of stopping and starting ADHD medications to remember:
- Stimulant medications vary in how long they stay in the body and are effective for symptoms.
- The dose of one medication isn’t the same as the dose of another medication.
- Don’t make dose adjustments or medication changes on your own.
- You’ll work closely with your healthcare team to find the right medication formulation and dose for you. Your body may take time to adjust to any changes.
Frequently asked questions about Vyvanse vs. Ritalin
Are Vyvanse and Ritalin the same?
No. While both are CNS stimulants used for ADHD, Vyvanse is a prodrug of dextroamphetamine, and Ritalin contains methylphenidate. They work differently in the brain but share many treatment uses and potential adverse effects.
Is Vyvanse or Ritalin better?
Studies have shown varying results for treatment effects and side effects. The best option depends on your needs and how you react to medications.
Can I use Vyvanse or Ritalin while pregnant?
Both are category C drugs and may carry risks during pregnancy. Tell your healthcare provider if you are pregnant or may become pregnant.
Can I use Vyvanse or Ritalin with alcohol?
Alcohol can increase stimulant effects and raise the risk of side effects.
Are there other kinds of treatment for ADHD?
There are other forms of ADHD medications, both stimulant and non-stimulant. Behavioral and lifestyle interventions are also an important part of treatment for many people.
What ADHD medication is comparable to Vyvanse?
Lisdexamfetamine, the active ingredient in Vyvanse and its generic formulations, is converted in the body to dextroamphetamine. Dextroamphetamine is the active ingredient in Adderall formulations. Adderall XR formulations, as well as their generics, typically have a once-daily dosing similar to Vyvanse.
- Data and Statistics on ADHD | Attention-Deficit / Hyperactivity Disorder, Centers for Disease Control and Prevention (2024)
- Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers, Front Neurosci (2013)
- Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison, European Child and Adolescent Psychiatry (2017)
- Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis, PLoS One (2020)
- FDA approves multiple generics of ADHD and BED treatment, Food and Drug Administration (2023)
- DailyMed – RITALIN- methylphenidate hydrochloride tablet, National Institutes of Health (2025)
- DailyMed – VYVANSE- lisdexamfetamine dimesylate capsule and tablet, National Institutes of Health (2023)
- How to Switch Stimulants: A Dosing Guide for ADHD, Psychiatric Times (2021)